Abstract
Many untreatable blinding diseases involve degeneration of retinal pigmented epithelial (RPE) cells, which has prompted exploration of the therapeutic potential of human-pluripotent-stem-cell-derived RPE. The first safety trials reported in The Lancet of embryonic-stem-cell-derived RPE cell transplants indicate no serious adverse outcomes and encourage further investigation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
